In atherosclerosis, remodelling of extracellular matrix (ECM) has long been considered a critical step in disease development/progression, but the multitude of cell types and molecular mechanisms involved is only now starting to emerge. In arteriosclerotic vascular disease, infiltrating leucocytes are known to release proteases, degrade the ECM, and lead to environmental changes allowing smooth muscle growth and plaque evolution. Among the enzymes secreted by leucocytes, a major role is played by elastases, which promote degradation of the elastin ring of arterial walls. This process triggers a tissue rearrangement that is more extensive than simple ECM destruction, because it triggers the production of elastin-derived peptides (EPs) that are not only degradation products, but also bioactive moieties evoking reactions in the surrounding tissues.
1 EPs, also known as elastokines, are a family of matrix fragments that possess cytokine-like functions and primarily signal via binding to a unusual cell surface receptor, the elastin receptor complex (ERC). The ERC is a heterotrimeric structure that includes an elastin binding protein, which binds elastin peptides, the protease cathepsin A and the membrane-bound neuraminidase, Neu-1. Upon elastin binding, different cell types, including those that actively participate to atherosclerosis development, organize an ERC complex that engages diverse signalling pathways, eventually converging on ERK1/2 activation. For instance, EPs control smooth muscle cell migration and proliferation, key determinants of plaque de/stabilization, via an ERC-dependent initiation of a Raf-1/MEK1/2/ERK1/2 cascade. EPs also affect fibroblast function and endothelial nitric oxide production, which limit atheromatous plaque formation. 2 Nonetheless, how ERC specifically triggers these signals has largely remained unknown. Recently, ERC has been reported to trigger the G protein-coupled receptor-activated phosphoinositide 3-kinase g (PI3Kg). 3 Given the ability of this lipid kinase to interact Gayral et al. extend their study to show that this process strictly relies on the activity of PI3Kg within leucocytes, as EPs fail to potentiate atherosclerosis development in chimeric ApoE 2/2 and LDLR 2/2 mice transplanted with PI3Kg 2/2 bone marrow. Intriguingly, PI3Kg-dependent chemotaxis and oxidative stress require neuraminidase activity, as evidenced by reduced disease severity of atherosclerotic mice carrying cathepsinA/neuroaminidase 1-deficient haematopoietic cells. 5 Although PI3Kg is proposed to provide the direct link between ERC and atherosclerosis development, the mechanism whereby this kinase is engaged remains to be elucidated. A plausible hypothesis posits that Neu-1-dependent glycosphingolipid production, a key event in ERC signalling, mediates activation of a selective G i -coupled receptor, which is typically involved in PI3Kg activation. 6 While EP-dependent triggering of Neu-1/PI3Kg signalling was found pivotal to atherogenesis in artificial models of exogenous EP administration, it is conceivable that the same mechanisms apply to contexts of endogenous EP production. Further studies will clarify whether GPCR signalling is involved and whether inhibition of EPs-mediated signalling events might function in vivo. module downstream leucocyte ERC activation during atherogenesis (Figure 1) . In humans, EP blood concentration increases during atherosclerosis and correlates with the degree and progression of vascular disease. 7 Therefore, targeting the ERC signal transduction machinery with Neu-1/PI3Kg inhibitors could be envisaged as a novel way of preventing the onset or limiting the progression of arterial diseases.
